The characteristics of androgen receptor splice variant 7 in the treatment of hormonal sensitive prostate cancer: a systematic review and meta-analysis.
Androgen receptor splicing variant 7
First-line hormonal therapy
Predictor
Prostate cancer
Prostatectomy
Survival
Journal
Cancer cell international
ISSN: 1475-2867
Titre abrégé: Cancer Cell Int
Pays: England
ID NLM: 101139795
Informations de publication
Date de publication:
2020
2020
Historique:
received:
07
01
2020
accepted:
23
04
2020
entrez:
12
5
2020
pubmed:
12
5
2020
medline:
12
5
2020
Statut:
epublish
Résumé
Accumulating evidence suggests androgen receptor splice variant 7 (AR-V7) may be associated with the prognosis of castration-resistant prostate cancer (CRPC) received novel hormonal therapy while its characteristic and prognosis value in hormonal sensitive prostate cancer is unclear. We aimed to evaluate the prognostic role of AR-V7 by progression free survival (PFS) and overall survival (OS) in hormonal sensitive prostate cancer (HSPC), and the AR-V7-positive-proportion difference in HSPC and CRPC. A search of PubMed, Embase, and the Web of Science was performed using the keywords prostate cancer, prostate tumor, prostate neoplasm, prostate carcinoma; AR-V7, AR3, androgen receptor splicing variant-7, or androgen receptor-3. Seventeen trials published due December 2019 were enrolled. AR-V7-positive proportion in CRPC was significantly larger than newly diagnosed prostate cancer (PCa) (odds ratio [OR] 7.06, 95% confidence interval [CI] 2.52-19.83, P < 0.001). Subgroup analyses indicated significantly higher AR-V7-positive proportion in CRPC derived from RNA in situ hybridization (OR 65.23, 95% CI 1.34-3171.43, P = 0.04), exosome RNA (OR 3.88, 95% CI 0.98-15.39, P = 0.05) and tissue RNA (OR 10.89, 95% CI 4.13-28.73, P < 0.001). AR-V7-positive patients had a significantly shorter PFS than those who were AR-V7-negative treated with first-line hormonal therapy (hazard ratio [HR] 3.63, 95% CI 1.85-7.10, P < 0.001) and prostatectomy (HR 2.49, 95% CI 1.33-4.64, P = 0.004). OS (HR 5.59, 95% CI 2.89-10.80, P < 0.001) were better in AR-V7-negative than AR-V7-positive HSPC patients treated with first-line hormonal therapy. The limitations of our meta-analysis were differences in study sample size and design, AR-V7 detection assay, and disease characteristics. AR-V7-positive proportion was significantly higher in CRPC than that in newly diagnosed PCa. AR-V7 positive HSPC patients portend worse prognosis of first-line hormonal therapy and prostatectomy. Additional studies are warranted to confirm these findings.
Sections du résumé
BACKGROUND
BACKGROUND
Accumulating evidence suggests androgen receptor splice variant 7 (AR-V7) may be associated with the prognosis of castration-resistant prostate cancer (CRPC) received novel hormonal therapy while its characteristic and prognosis value in hormonal sensitive prostate cancer is unclear.
METHODS
METHODS
We aimed to evaluate the prognostic role of AR-V7 by progression free survival (PFS) and overall survival (OS) in hormonal sensitive prostate cancer (HSPC), and the AR-V7-positive-proportion difference in HSPC and CRPC. A search of PubMed, Embase, and the Web of Science was performed using the keywords prostate cancer, prostate tumor, prostate neoplasm, prostate carcinoma; AR-V7, AR3, androgen receptor splicing variant-7, or androgen receptor-3. Seventeen trials published due December 2019 were enrolled.
RESULTS
RESULTS
AR-V7-positive proportion in CRPC was significantly larger than newly diagnosed prostate cancer (PCa) (odds ratio [OR] 7.06, 95% confidence interval [CI] 2.52-19.83, P < 0.001). Subgroup analyses indicated significantly higher AR-V7-positive proportion in CRPC derived from RNA in situ hybridization (OR 65.23, 95% CI 1.34-3171.43, P = 0.04), exosome RNA (OR 3.88, 95% CI 0.98-15.39, P = 0.05) and tissue RNA (OR 10.89, 95% CI 4.13-28.73, P < 0.001). AR-V7-positive patients had a significantly shorter PFS than those who were AR-V7-negative treated with first-line hormonal therapy (hazard ratio [HR] 3.63, 95% CI 1.85-7.10, P < 0.001) and prostatectomy (HR 2.49, 95% CI 1.33-4.64, P = 0.004). OS (HR 5.59, 95% CI 2.89-10.80, P < 0.001) were better in AR-V7-negative than AR-V7-positive HSPC patients treated with first-line hormonal therapy. The limitations of our meta-analysis were differences in study sample size and design, AR-V7 detection assay, and disease characteristics.
CONCLUSION
CONCLUSIONS
AR-V7-positive proportion was significantly higher in CRPC than that in newly diagnosed PCa. AR-V7 positive HSPC patients portend worse prognosis of first-line hormonal therapy and prostatectomy. Additional studies are warranted to confirm these findings.
Identifiants
pubmed: 32390764
doi: 10.1186/s12935-020-01229-4
pii: 1229
pmc: PMC7201592
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
149Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Competing interestsThe authors have declared that no competing interest exists.
Références
Scand J Urol. 2019 Dec;53(6):365-371
pubmed: 31809622
Eur Urol. 2016 Oct;70(4):599-608
pubmed: 27117751
Eur Urol. 2020 Feb;77(2):170-177
pubmed: 31648903
Prostate. 2017 Jan;77(1):60-71
pubmed: 27550197
Cancer Cell. 2009 Dec 8;16(6):458-62
pubmed: 19962664
Nat Clin Pract Urol. 2009 Feb;6(2):76-85
pubmed: 19198621
JAMA Oncol. 2016 Nov 1;2(11):1441-1449
pubmed: 27262168
PLoS One. 2011 Apr 28;6(4):e19059
pubmed: 21552559
Clin Cancer Res. 2017 Jan 15;23(2):363-369
pubmed: 27440270
Transl Androl Urol. 2015 Jun;4(3):365-80
pubmed: 26814148
Lancet. 2016 Mar 19;387(10024):1163-77
pubmed: 26719232
Eur Urol. 2015 Dec;68(6):939-45
pubmed: 26188394
Lancet Oncol. 2013 Feb;14(2):149-58
pubmed: 23306100
Ann Oncol. 2015 Sep;26(9):1859-1865
pubmed: 26117829
PLoS One. 2011;6(11):e27970
pubmed: 22114732
PLoS Med. 2009 Jul 21;6(7):e1000100
pubmed: 19621070
CA Cancer J Clin. 2002 May-Jun;52(3):154-79
pubmed: 12018929
J Clin Invest. 2019 Jan 2;129(1):192-208
pubmed: 30334814
Cancer Res. 2009 Jan 1;69(1):16-22
pubmed: 19117982
Sci Rep. 2015 Jan 07;5:7654
pubmed: 25563505
Urol Oncol. 2017 Mar;35(3):123
pubmed: 28159490
Cancer Res. 2009 Mar 15;69(6):2305-13
pubmed: 19244107
Res Rep Urol. 2016 Jan 28;8:21-5
pubmed: 26870716
Cells. 2019 Jul 08;8(7):
pubmed: 31288377
Eur Urol. 2018 May;73(5):715-723
pubmed: 29258679
Urol Oncol. 2016 Nov;34(11):520
pubmed: 26964769
Eur Urol. 2018 May;73(5):727-735
pubmed: 28866255
Cell Mol Life Sci. 2011 Dec;68(24):3971-81
pubmed: 21748469
Eur Urol Focus. 2018 Jul;4(4):529-539
pubmed: 28753843
Mod Pathol. 2018 Jan;31(1):198-208
pubmed: 29076496
Cancer Res. 2008 Jul 1;68(13):5469-77
pubmed: 18593950
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Eur Urol. 2018 Apr;73(4):572-582
pubmed: 29129398
Br J Cancer. 2018 Aug;119(3):347-356
pubmed: 29988112
JAMA Oncol. 2015 Aug;1(5):582-91
pubmed: 26181238
Lab Chip. 2018 Dec 18;19(1):87-97
pubmed: 30500003
Eur Urol. 2016 Aug;70(2):256-62
pubmed: 26610858
Curr Opin Pharmacol. 2008 Aug;8(4):440-8
pubmed: 18674639
J Clin Oncol. 2017 Jul 1;35(19):2149-2156
pubmed: 28384066
Asian J Androl. 2016 Jul-Aug;18(4):580-5
pubmed: 27174161